De Novo Variants Disturbing the Transactivation Capacity of POU3F3 Cause a Characteristic Neurodevelopmental Disorder.
BRET assay
Brain-1
FOXP2
POU3F2
POU3F3
de novo variants
intellectual disability
luciferase reporter
speech/language disorder
Journal
American journal of human genetics
ISSN: 1537-6605
Titre abrégé: Am J Hum Genet
Pays: United States
ID NLM: 0370475
Informations de publication
Date de publication:
01 08 2019
01 08 2019
Historique:
received:
10
02
2019
accepted:
07
06
2019
pubmed:
16
7
2019
medline:
17
3
2020
entrez:
16
7
2019
Statut:
ppublish
Résumé
POU3F3, also referred to as Brain-1, is a well-known transcription factor involved in the development of the central nervous system, but it has not previously been associated with a neurodevelopmental disorder. Here, we report the identification of 19 individuals with heterozygous POU3F3 disruptions, most of which are de novo variants. All individuals had developmental delays and/or intellectual disability and impairments in speech and language skills. Thirteen individuals had characteristic low-set, prominent, and/or cupped ears. Brain abnormalities were observed in seven of eleven MRI reports. POU3F3 is an intronless gene, insensitive to nonsense-mediated decay, and 13 individuals carried protein-truncating variants. All truncating variants that we tested in cellular models led to aberrant subcellular localization of the encoded protein. Luciferase assays demonstrated negative effects of these alleles on transcriptional activation of a reporter with a FOXP2-derived binding motif. In addition to the loss-of-function variants, five individuals had missense variants that clustered at specific positions within the functional domains, and one small in-frame deletion was identified. Two missense variants showed reduced transactivation capacity in our assays, whereas one variant displayed gain-of-function effects, suggesting a distinct pathophysiological mechanism. In bioluminescence resonance energy transfer (BRET) interaction assays, all the truncated POU3F3 versions that we tested had significantly impaired dimerization capacities, whereas all missense variants showed unaffected dimerization with wild-type POU3F3. Taken together, our identification and functional cell-based analyses of pathogenic variants in POU3F3, coupled with a clinical characterization, implicate disruptions of this gene in a characteristic neurodevelopmental disorder.
Identifiants
pubmed: 31303265
pii: S0002-9297(19)30232-0
doi: 10.1016/j.ajhg.2019.06.007
pmc: PMC6698880
pii:
doi:
Substances chimiques
POU Domain Factors
0
POU3F3 protein, human
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
403-412Subventions
Organisme : NHGRI NIH HHS
ID : UM1 HG008900
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007748
Pays : United States
Informations de copyright
Copyright © 2019 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.
Références
Eur J Biochem. 2000 Nov;267(21):6413-22
pubmed: 11029584
J Mol Biol. 2000 Oct 6;302(5):1023-39
pubmed: 11183772
Nature. 2001 Oct 4;413(6855):519-23
pubmed: 11586359
Science. 2002 Feb 22;295(5559):1528-32
pubmed: 11859196
Genes Dev. 2002 Jul 15;16(14):1760-5
pubmed: 12130536
Biochem Pharmacol. 2002 Sep;64(5-6):979-84
pubmed: 12213595
Nat Genet. 2004 Aug;36(8):801-8
pubmed: 15284851
Dev Cell. 2006 Dec;11(6):831-44
pubmed: 17141158
Annu Rev Biochem. 2007;76:51-74
pubmed: 17352659
Am J Hum Genet. 2009 Apr;84(4):524-33
pubmed: 19344873
Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10171-6
pubmed: 19520826
Proteins. 2011 Feb;79(2):674-7
pubmed: 21117060
Cereb Cortex. 2013 Nov;23(11):2632-43
pubmed: 22892427
Mol Biol Evol. 2013 Apr;30(4):844-52
pubmed: 23197593
Mol Syndromol. 2014 Jan;5(1):32-5
pubmed: 24550763
J Vis Exp. 2014 May 26;(87):null
pubmed: 24893771
Hum Mutat. 2015 Oct;36(10):928-30
pubmed: 26220891
Science. 1989 Jul 28;245(4916):371-8
pubmed: 2667136
Am J Hum Genet. 2016 Feb 4;98(2):363-72
pubmed: 26833329
Nature. 1989 Jul 6;340(6228):35-41
pubmed: 2739723
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Trends Genet. 2017 Sep;33(9):642-656
pubmed: 28781152
Neuropediatrics. 2018 Dec;49(6):401-404
pubmed: 30199896
Genes Dev. 1993 Dec;7(12B):2483-96
pubmed: 8276233
J Mol Evol. 1996 Sep;43(3):170-8
pubmed: 8703082
Brain Res. 1997 Mar 28;752(1-2):261-8
pubmed: 9106466
J Biol Chem. 1998 Dec 18;273(51):34196-205
pubmed: 9852081